Melinta Therapeutics


Melinta Therapeutics
HeadquartersMorristown, NJ
Area served
ProductsBroad-spectrum antibiotics

Melinta Therapeutics, founded in 2000 as Rib-X Pharmaceuticals, is an American publicly traded biopharmaceutical firm that focuses on the design and development of novel broad-spectrum antibiotics for the treatment of antibiotic-resistant infections in hospital and community settings. The company is located in New Haven, Connecticut.[1]

In mid-2011, Sanofi entered into a global research collaboration and licensing option with the company to develop and commercialize novel antibiotics.[2] It was renamed Melinta Therapeutics in 2013.[3]

One of its products, delafloxacin (Baxdela), a fluoroquinolone antibiotic acquired from Wakunaga Pharmaceutical in 2006,[2] was approved by the FDA in 2017.[4]

As of 2016, the company was also developing radezolid, a next-generation oxazolidinone for bacterial acne.[3]

Melinta moved its headquarters to Morristown, New Jersey in early 2019.

On December 27, 2019, Melinta Therapeutics filed for Chapter 11 bankruptcy protection.[5]


  1. ^ Carroll, John (2011). "Rib-X Pharmaceuticals - 2011 Fierce 15". FierceBiotech.
  2. ^ a b Cartwright, Heather (12 July 2011). "Rib-X Pharmaceuticals Signs Global Antibiotic Research Collaboration with Sanofi". PharmaDeals Review. No. 7. doi:10.3833/pdr.v2011i7.1494. Archived from the original on 25 April 2012.
  3. ^ a b Stearns, John (August 1, 2016). "Melinta Therapeutics takes aim at deadly drug-resistant bacteria". Hartford Business Journal.
  4. ^ Osborne, Randy (20 June 2017). "Melinta's I.V., oral delafloxacin wins FDA nod in skin infections". BioWorld.
  5. ^ "Antibiotics maker Melinta files for Chapter 11 bankruptcy". Reuters. 2019-12-27. Retrieved 2019-12-29.

External links

  • Official website

Coordinates: 40°48′06″N 74°27′31″W / 40.80164°N 74.45860°W / 40.80164; -74.45860